[en] The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Precision for document type :
Review article
Disciplines :
Hematology
Author, co-author :
Davies, Faith E ; Perlmutter Cancer Center, NYU Langone, New York, New York.
Pawlyn, Charlotte ; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United ; The Royal Marsden Hospital, Department of Haematology, London, United Kingdom.
Usmani, Saad Z; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center,
San-Miguel, Jesus F ; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
Einsele, Hermann; Department of Internal Medicine II, University Hospital Würzburg, Würzburg,
Boyle, Eileen M ; Perlmutter Cancer Center, NYU Langone, New York, New York.
Corre, Jill ; Unité de Génomique du Myélome, Institut Universitaire du Cancer, Toulouse France.
Auclair, Daniel; The Multiple Myeloma Research Foundation, Norwalk, Connecticut.
Cho, Hearn Jay ; The Multiple Myeloma Research Foundation, Norwalk, Connecticut. ; Multiple Myeloma Center of Excellence, Icahn School of Medicine at Mt. Sinai, New
Lonial, Sagar; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory
Sonneveld, Pieter; Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, the
Stewart, A Keith; University Health Network and the Princess Margaret Cancer Centre, Toronto,
Bergsagel, P Leif ; Department of Medicine, Mayo Clinic, Arizona.
Kaiser, Martin F ; The Royal Marsden Hospital, Department of Haematology, London, United Kingdom. ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London
Weisel, Katja; Department of Oncology, Hematology and Bone Marrow Transplantation with Section
Keats, Jonathan J ; Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix
Mikhael, Joseph R ; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix
Ghobrial, Irene M; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical
Orlowski, Robert Z ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
Landgren, C Ola ; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami
Gay, Francesca ; Division of Hematology, University of Torino, Torino, Italy.
Caers, Jo ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Chng, Wee Joo ; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology ; Department of Hematology, Mayo Clinic, Rochester, Minnesota. ; Division of Hematology and Oncology, Department of Medicine, University of
Chari, Ajai ; Multiple Myeloma Center of Excellence, Icahn School of Medicine at Mt. Sinai, New
Walker, Brian A ; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology
Kumar, Shaji K ; Department of Hematology, Mayo Clinic, Rochester, Minnesota.
Costa, Luciano J ; Division of Hematology and Oncology, Department of Medicine, University of
Anderson, Kenneth C ; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical
Morgan, Gareth J ; Perlmutter Cancer Center, NYU Langone, New York, New York.
